Ebpay生命医药出版社

Ebpay生命

100763

论文已发表

提 交 论 文


注册即可获取Ebpay生命的最新动态

注 册



IF 收录期刊



  • 3.3 Breast Cancer (Dove Med Press)
  • 3.4 Clin Epidemiol
  • 2.5 Cancer Manag Res
  • 2.9 Infect Drug Resist
  • 3.5 Clin Interv Aging
  • 4.7 Drug Des Dev Ther
  • 2.7 Int J Chronic Obstr
  • 6.6 Int J Nanomed
  • 2.5 Int J Women's Health
  • 2.5 Neuropsych Dis Treat
  • 2.7 OncoTargets Ther
  • 2.0 Patient Prefer Adher
  • 2.3 Ther Clin Risk Manag
  • 2.5 J Pain Res
  • 2.8 Diabet Metab Synd Ob
  • 2.8 Psychol Res Behav Ma
  • 3.0 Nat Sci Sleep
  • 1.8 Pharmgenomics Pers Med
  • 2.7 Risk Manag Healthc Policy
  • 4.2 J Inflamm Res
  • 2.1 Int J Gen Med
  • 4.2 J Hepatocell Carcinoma
  • 3.7 J Asthma Allergy
  • 1.9 Clin Cosmet Investig Dermatol
  • 2.7 J Multidiscip Healthc



更多详情 >>





已发表论文

Emo@KP MBs 顺利获得原位微纳转化调节 TGF-β1/Smad 信号通路以减轻单侧输尿管梗阻所致的肾炎症和纤维化

 

Authors Zhang J, Xie X, Li Y, Wang H , Zhang L, Shi P, Wei J, Zhang L, Lu Y, Cui L, Liu X, Liang X

Received 7 October 2024

Accepted for publication 4 March 2025

Published 24 March 2025 Volume 2025:20 Pages 3731—3747

DOI http://doi.org/10.2147/IJN.S499550

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Yan Shen

Jinxia Zhang,1,2,* Xinxin Xie,2,* Yuanjing Li,1,* Haonan Wang,2 Lijuan Zhang,1 Peiqi Shi,1 Jing Wei,1 Ling Zhang,1 Yingdong Lu,1 Ligang Cui,2 Xiaoning Liu,1 Xiaolong Liang2 

1Department of Ultrasound, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, People’s Republic of China; 2Department of Ultrasound, Peking University Third Hospital, Beijing, 100191, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Xiaoning Liu, Email liuxn_angel2023@163.com Xiaolong Liang, Email xiaolong_liang@bjmu.edu.cn

Introduction: Emodin alleviates renal interstitial fibrosis (RIF) and reduces inflammation by inhibiting the TGF-β 1/Smad pathway, thus improving CKD outcomes. However, its clinical use is limited due to poor solubility and side effects. This study developed a targeted drug delivery system using αKIM-1 modified microbubbles carrying Emodin to enhance accumulation in renal tissues with high KIM-1 expression.
Methods: Emo@KP MBs were characterized by TEM and DLS, and their drug loading and encapsulation rates were measured by UV-VIS-NIR spectroscopy. Biocompatibility was assessed in vitro with HK-2 cells and in vivo via hematological and pathological markers. Contrast-enhanced ultrasound (CEUS) and fluorescence imaging were used for real-time visualization of treatment. Therapeutic experiments were performed on a unilateral ureteral obstruction (UUO) mouse model treated with Emo@KP MBs + US on days 1 and 3 post-surgery. Renal function, cytokine levels, and histological analysis were detected to evaluate therapeutic effects.
Results: Emo@KP MBs exhibited spherical structures (2 ~ 4 μm) with good stability. Ultrasound targeted microbubble destruction (UTMD) enabled controlled release of Emodin. CEUS and fluorescence imaging showed enhanced drug accumulation in diseased kidneys. In the UUO + Emo@KP MBs/US group, renal function was improved, inflammatory cytokines (IL-1β, TNF-α) were decreased, and renal lesions and collagen deposition were reduced. Immunohistochemistry revealed the downregulation of TGF-β, Smad2/3, and α-SMA, and upregulation of E-cadherin.
Conclusion: Emo@KP MBs enhanced drug delivery efficiency and therapeutic efficacy through αKIM-1 targeting and UTMD, while providing real-time imaging capabilities, suggesting good potential as a therapeutic approach to reduce renal inflammation and fibrosis in UUO.

Keywords: unilateral ureteral obstruction, renal interstitial fibrosis, microbubbles, UTMD, Emodin, αKIM-1

Download Article[PDF]